ptx-covid19-b
Vaccineexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jan 14, 2021 (NCT04765436)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05534048 | Phase 3 | Feb 3, 2023 | Everest Medicines |
| NCT05534035 | Phase 3 | Feb 3, 2023 | Everest Medicines |
| NCT05175742 | Phase 2 | Aug 17, 2021 | Providence Therapeutics Holdings Inc. |
| NCT04765436 | Phase 1 | Jan 14, 2021 | Providence Therapeutics Holdings Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Everest Medicines | For profit | 2 | 2 | 1 | 2023 |
| Providence Therapeutics Holdings Inc. | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1